Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Monday, July 24, 2017
 
Recommended for you
Stocks to watch next week
Seeking Alpha • Jason Aycock
Gilead Has Another Ace Up Its Sleeve
Seeking Alpha • Long Term Bio
Gilead Sciences' Shares Just Answered The Question
Seeking Alpha • James Brumley
Red Numbers In Your Portfolio Can Be Scary, But They Don't Have To Be
Seeking Alpha • The Dividend Bro
Gilead At 30: Re-Entry Time
Seeking Alpha • Out
Take Profits On Gilead
Seeking Alpha • Giovanni Dimauro
FDA approves Gilead's drug for chronic hep C patients
Reuters
Wiley joins OFW Law
Politico • Theodoric Meyer
Fish & Richardson Set to Receive $12.5M Fee Award in Gilead-Merck Infringement Battle
The American Lawyer • Scott Flaherty
Fastest-Growing U.S. Drug Spender Medicaid In Danger Of Cuts
Seeking Alpha • E.P. Vantage
 
Recommended for You
Charter Communications, Federal Reserve
Stocks to watch next week
Seeking AlphaJason Aycock
Key events are scheduled for the companies listed below next week. Fed watch: The Fed Open Market Committee meets Tuesday and Wednesday, July 25 and 26, and will produce a monetary policy statement at 2 p.m. on July 26. Notable earnings reports:...
Share
Gilead Sciences, Health Finance
Gilead Has Another Ace Up Its Sleeve
Seeking AlphaLong Term Bio
Summary Approval of Vosevi should help the company produce more sales in Hep C space. Two phase 3 studies show that Vosevi can be a contender. Combination drug from another company looks to steal market share. Recently, Gilead Sciences (GILD) announced it...
Share
Gilead Sciences, Health Finance
Gilead Sciences' Shares Just Answered The Question
Seeking AlphaJames Brumley
Summary GILD stock has completed a month-long effort to clear a key technical hurdle, getting over the hump this week. The necessary value needed for a rally has been in place for quite some time, but has been ignored as shares were...
Share
Finance, Gilead Sciences
Red Numbers In Your Portfolio Can Be Scary, But They Don't Have To Be
Seeking AlphaThe Dividend Bro
Summary In my early investing days, a drop in share price would've had me running for the hills. When a stock you like drops in price, it can be a buying opportunity. This just occurred earlier this year with Nike. Gilead, Target,...
Share
Gilead Sciences, Health Finance
Gilead At 30: Re-Entry Time
Seeking AlphaOut
Summary Gilead has undergone huge stress from transitory dislocutions in its revenue stream generated by its uber-successful HCV cure trio (now a quartet). In its first 30 years, Gilead has earned a sobriquet as one of the world's most successful biotechs. During...
Share
Economic Policy, Gilead Sciences
Take Profits On Gilead
Seeking AlphaGiovanni Dimauro
Summary Gilead Earnings report could bring wild swings. One option Play that made over 400%, ripe for profit taking. Earnings report will likely test investors long and short. Next week's earnings report by Gilead Sciences (NYSE:GILD) will likely bring moments of extreme...
Share
Gilead Sciences, Health Care Industry
FDA approves Gilead's drug for chronic hep C patients
Reuters
() - Gilead Sciences Inc said on Tuesday that the U.S. Food and Drug Administration approved its hepatitis C drug for patients who had failed to respond to prior treatments. Vosevi is the first drug to be approved for hepatitis C patients...
Share
Gilead Sciences, Lobbying
Wiley joins OFW Law
PoliticoTheodoric Meyer
With David Beavers and Aubree Eliza Weaver OFW LAW SNAGS LADD WILEY: Ladd Wiley has left Akin Gump to start a new health industry policy and regulatory practice at OFW Law (formerly known as Olsson, Frank, Weeda, Terman & Matz). Wiley, a...
Share
Gilead Sciences, Merck & Co., Inc.
Fish & Richardson Set to Receive $12.5M Fee Award in Gilead-Merck Infringement Battle
The American Lawyer Scott Flaherty
Fish & Richardson and client Gilead Sciences Inc. are slated to receive nearly $14 million in legal fees after exposing patent misconduct by Merck & Co. Inc. that helped Gilead shake off a $200 million infringement verdict. Benefits include: Unlimited access to...
Share
Gilead Sciences, GlaxoSmithKline plc
Fastest-Growing U.S. Drug Spender Medicaid In Danger Of Cuts
Seeking AlphaE.P. Vantage
The US Congress' bid to reshape health insurance holds many perils for the biopharma sector, but perhaps none is more significant than a proposed reduction in Medicaid funding that would see enrollment in the program for low-income and disabled people drop by...
Share